Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Consolidated Net Income: 2020-2025

Historic Consolidated Net Income for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's Consolidated Net Income rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
  • Per Pharming Group N.V's latest filing, its Consolidated Net Income stood at $90.2 million for Q3 2025, which was up 856.29% from $9.4 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Consolidated Net Income registered a high of $90.2 million during Q3 2025, and its lowest value of -$25.7 million during Q3 2021.
  • For the 3-year period, Pharming Group N.V's Consolidated Net Income averaged around $5.1 million, with its median value being $3.4 million (2023).
  • Per our database at Business Quant, Pharming Group N.V's Consolidated Net Income spiked by 29,235.91% in 2022 and then slumped by 463.64% in 2023.
  • Over the past 5 years, Pharming Group N.V's Consolidated Net Income (Quarterly) stood at $5.7 million in 2021, then tumbled by 132.35% to -$1.8 million in 2022, then soared by 375.83% to $5.1 million in 2023, then climbed by 28.20% to $6.5 million in 2024, then surged by 1,255.41% to $90.2 million in 2025.
  • Its Consolidated Net Income stands at $90.2 million for Q3 2025, versus $9.4 million for Q2 2025 and $6.5 million for Q4 2024.